Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

BACKGROUND: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776974/
https://ncbi.nlm.nih.gov/pubmed/23963139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.409
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares